This is a double-blind, randomised, crossover trial designed to compare the effect of HLA epitope-matched (HEM) with standard HLA-matched (HSM) prophylactic platelet transfusions in raising the platelet count increment after transfusion in alloimmunised thrombocytopenic patients with aplastic anaemia (AA), myelodysplasia (MDS), or acute myelodysplastic leukaemia (AML).
HEM platelets will be selected using the HLAMatchmaker epitope matching programme. Patients will be randomised to receive five pairs of HEM and HSM platelet transfusions in random order. Patients, treating clinicians and clinical staff will be blinded to the type of platelets patients receive. Blinding will be maintained by ensuring that both HEM and HSM platelets are in identical standard packages and have identical standard labels.
The NHSBT H&I issuing laboratory will assign the randomised treatment schedule, thus the H&I laboratory staff will not be blinded. Each NHSBT H&I issuing laboratory computer will hold a list of study numbers and corresponding randomised treatment schedule assigned to each study number.
Tel: 07471 147868
Marsh JCW, Kallon D, Brown C, Gilbertson A, Pigden C, Deary AJ, Mora A, Brown J, Laing E, Pankhurst L, Choo L, Hodge R, Llewelyn C, Harding K, Sage D, Mijovic A, Mufti GJ, Stanworth SJ, Navarrete CV. National randomised trial of HLA epitope matched platelet transfusions for alloimmunised patients with myeloid bone marrow disorders. British Blood Transfusion Society Meeting November 11th 2015
JCW Marsh, D Kallon, C Brown, C Pigden, A Deary, K Harding, L Choo, C LLewelyn, A Mijovic, GJ Mufti, S Stanworth, C Navarrete. Application of HLAMatchmaker computer programme to select HLA epitope matched platelets for alloimmunised thrombocytopenic patients with aplastic anaemia, MDS and acute myeloid leukaemia. British Haematological Society Annual Scientific Meeting 2014
C Pigden and D Kallon HLA-Epitope: Trial of HLA epitope-matched platelets in patients with aplastic anaemia, myelodysplastic syndrome and acute myeloid leukaemia. On behalf of the TMG of the HLA Epitope Trial. Blood and Transplant Matters October 2014